NCT03561870 (OLAGLI) is a Phase 2 clinical trial of Olaparib 150 MG in Recurrent IDH, sponsored by Hospices Civils de Lyon.

Who is sponsoring NCT03561870?

NCT03561870 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT03561870?

Interventions in NCT03561870: Olaparib 150 MG.

What condition does NCT03561870 study?

NCT03561870 studies Recurrent IDH, Mutant High Grade Glioma.

Is NCT03561870 still recruiting?

NCT03561870 is currently completed. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT03561870: OLAGLI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olaparib in Recurrent IDH-mutant Glioma

Completed Phase 2 Last updated 12 September 2025

What this trial tests

Phase 2 trial testing Olaparib 150 MG in Recurrent IDH in 35 participants. Completed in 24 November 2021.

Timeline

20 March 2019

Primary endpoint
8 November 2021

24 November 2021

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	20 March 2019
Primary completion	8 November 2021
Estimated completion	24 November 2021
Sites	1 location across France

Drugs / interventions tested

Olaparib 150 MG — full drug profile →

Conditions studied

Recurrent IDH — all drugs for Recurrent IDH →
Mutant High Grade Glioma — all drugs for Mutant High Grade Glioma →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Recurrent IDH or Mutant High Grade Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recent data demonstrate that in IDH-mutant gliomas, 2 hydroxy-glutarate production induces a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors, including olaparib (Lynparza; AstraZeneca). The aim of this open-label phase 2 study is to evaluate the efficacy of olaparib in in recurrent IDH-mutant high grade gliomas based on 6 months progression-free survival.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Lower Grade Gliomas.
Youssef G, Miller JJ. · · 2020 · cited 97× · PMID 32444979 · DOI 10.1007/s11910-020-01040-8
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Wang Y, Wild AT, Turcan S, Wu WH, et al · · 2020 · cited 77× · PMID 32494639 · DOI 10.1126/sciadv.aaz3221
Targeting DNA repair in cancer: current state and novel approaches.
Klinakis A, Karagiannis D, Rampias T. · · 2020 · cited 69× · PMID 31612241 · DOI 10.1007/s00018-019-03299-8
<i>IDH</i> Mutations in Glioma: Double-Edged Sword in Clinical Applications?
Kayabolen A, Yilmaz E, Bagci-Onder T. · · 2021 · cited 58× · PMID 34356864 · DOI 10.3390/biomedicines9070799
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Rominiyi O, Collis SJ. · · 2022 · cited 31× · PMID 34036721 · DOI 10.1002/1878-0261.13020
Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R, de la Fuente MI. · · 2023 · cited 26× · PMID 37060388 · DOI 10.1007/s11910-023-01265-3
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, et al · · 2023 · cited 25× · PMID 35973817 · DOI 10.1093/neuonc/noac205
DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets.
Ozair A, Bhat V, Alisch RS, Khosla AA, et al · · 2023 · cited 24× · PMID 36831683 · DOI 10.3390/cancers15041342

Verify or expand the search:

Other trials of Olaparib 150 MG

Trials testing the same drug.

NCT07069335 — A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Su · Phase 1 · recruiting
NCT06078787 — Olaparib in PALB2 Advanced Pancreatic Cancer · Phase 2 · recruiting

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03561870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03561870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing